Study summary
Adding radium-223 to enzalutamide extended life for men with bone metastases
42.3months median survival, vs 35.0 with enzalutamide alone
What was tested
Enzalutamide with or without six injections of radium-223, a radioactive drug that targets bone, as first treatment for castration-resistant prostate cancer with bone metastases. Bone-protecting drugs were required.
What they found
- Median overall survival was 42.3 vs 35.0 months at the interim analysis.
- Fractures were more common (24.3% vs 13.4%), so bone protection matters.
What it means
A new combination option for bone-only or bone-predominant disease.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.